SOHO 2021 | Progress in the treatment of TP53 mutated AML
TP53 mutated acute myeloid leukemia (AML) is notoriously hard to treat, as it responds poorly to many chemotherapy techniques, and the overall survival (OS) of patients with this AML is low. However, Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses promising results from research into the treatment of TP53-mutated AML. Dr Daver talks on anti-CD47 monoclonal antibodies including magrolimab in combination with azacytidine and venetoclax which has yielded response rates of 70% and complete remission rates of approximately 50%. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Naval Daver, MD, has received research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen and has served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck labs, and Agios.
